Respiratory Medicine Department, Wuhou District People's Hospital, Chengdu, China.
Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Immunol. 2024 May 10;15:1398927. doi: 10.3389/fimmu.2024.1398927. eCollection 2024.
Selinexor, a selective inhibitor of nuclear export (SINE), is gaining recognition beyond oncology for its potential in anti-inflammatory therapy. This review elucidates Selinexor's dual action, highlighting its anti-tumor efficacy in various cancers including hematologic malignancies and solid tumors, and its promising anti-inflammatory effects. In cancer treatment, Selinexor has demonstrated benefits as monotherapy and in combination with other therapeutics, particularly in drug-resistant cases. Its role in enhancing the effectiveness of bone marrow transplants has also been noted. Importantly, the drug's impact on key inflammatory pathways provides a new avenue for the management of conditions like sepsis, viral infections including COVID-19, and chronic inflammatory diseases such as Duchenne Muscular Dystrophy and Parkinson's Disease. The review emphasizes the criticality of managing Selinexor's side effects through diligent dose optimization and patient monitoring. Given the complexities of its broader applications, extensive research is called upon to validate Selinexor's long-term safety and effectiveness, with a keen focus on its integration into clinical practice for a diverse spectrum of disorders.
Selinexor，一种核输出（SINE）的选择性抑制剂，除了在肿瘤学领域，因其在抗炎治疗方面的潜力而受到关注。本综述阐明了 Selinexor 的双重作用，突出了其在各种癌症（包括血液系统恶性肿瘤和实体瘤）中的抗肿瘤疗效，以及其有前景的抗炎作用。在癌症治疗中，Selinexor 作为单一疗法和与其他疗法联合应用均显示出益处，特别是在耐药病例中。它在增强骨髓移植效果方面的作用也得到了关注。重要的是，该药物对关键炎症途径的影响为治疗脓毒症、包括 COVID-19 在内的病毒感染以及杜氏肌营养不良症和帕金森病等慢性炎症性疾病等疾病提供了新的途径。该综述强调了通过仔细优化剂量和患者监测来管理 Selinexor 的副作用的重要性。鉴于其更广泛应用的复杂性，需要进行广泛的研究来验证 Selinexor 的长期安全性和有效性，并特别关注其在各种疾病中的临床实践整合。
